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Sterol 27-hydroxylase (CYP27A1) is a key enzyme in bile acids (BAs) biosynthesis and a
regulator of cholesterol metabolism. Cyp27a1/Apolipoprotein E double knockout (DKO)
mice fed with western diet (WD) are protected from atherosclerosis via up-regulation of
hepatic Cyp7a1 and Cyp3a11. Since feeding BAs ameliorates metabolic changes in
Cyp27a1 KO mice, we tested BAs feeding on the development of atherosclerosis in DKO
mice. DKO mice were fed for 8 weeks with WD containing 0.1% cholic acid (CA) (WD-CA)
or chenodeoxycholic acid (CDCA) (WD-CDCA). Atherosclerotic lesions, plasma
lipoprotein composition and functionality, hepatic lipid content, BAs amount and
composition, expression of genes involved in lipid metabolism and BA signaling in liver
and intestine as well as intestinal cholesterol absorption were assessed. Hepatic Cyp7a1
and Cyp3a11 expression were reduced by 60% after feeding with both WD-CA and WD-
CDCA. After feeding with WD-CA we observed a 40-fold increase in the abundance of
atherosclerotic lesions in the aortic valve, doubling of the levels of plasma total and low
density lipoprotein cholesterol and halving of the level of high density lipoprotein
cholesterol. Furthermore, in these mice plasma cholesterol efflux capacity decreased by
30%, hepatic BA content increased 10-fold, intestinal cholesterol absorption increased 6-
fold. No such changes were observed in mice fed with WD-CDCA. Despite similar
reduction on Cyp7a1 and Cyp3a11 hepatic expression, CA and CDCA have a
drastically different impact on development of atherosclerosis, plasma and hepatic
lipids, BAs composition and intestinal absorption. Reduced cholesterol absorption
contributes largely to athero-protection in DKO mice.
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Sterol 27-hydroxylase (CYP27A1) is a mitochondrial enzyme
ubiquitously expressed which belongs to the cytochrome P450
family. It catalyzes the hydroxylation of cholesterol at C27 to
form 27-hydroxycholesterol (27-OHC) and cholestenoic acid (1,
2). CYP27A1 plays a major role in cholesterol homeostasis. In
the liver, it is involved in pathways of cholesterol metabolism due
to its role in bile acids (BAs) biosynthesis. CYP27A1 catalyzes the
first step of the alternative pathway of BAs synthesis, as well as
intermediate steps of the classical pathway initiated by
cholesterol 7a-hydroxylase (CYP7A1) (3, 4). CYP7A1 acts not
only as the key enzyme for cholesterol metabolism, it is also the
rate-limiting enzyme for BAs biosynthesis in the liver (5). In
extrahepatic tissues, CYP27A1 is involved in reverse cholesterol
transport, since overexpression in macrophages enhances
cholesterol efflux, the transfer of cholesterol to an acceptor in
plasma, both in vitro and in vivo (6–8). Finally, CYP27A1
regulates cholesterol biosynthesis, as 27-OHC was shown to act
in vitro as negative feedback regulator on the rate limiting
enzyme of cholesterol biosynthesis, the 3-Hydroxy-3-
Methylglutaryl-Coenzym-A-Reductase (HMGCR) (9).
Given the role of CYP27A1 in cholesterol efflux and BAs
synthesis, we investigated the effect of Cyp27a1 deficiency on the
development of atherosclerosis in Apolipoprotein E (ApoE)
knock out (KO) mice, anticipating that atherosclerotic lesions
would be increased in Cyp27A1 KO/ApoE KO double knockout
(DKO) mice. ApoE KO mice develop accelerated atherosclerosis,
especially when fed with pro-atherogenic western diet (WD), but
the atherosclerotic phenotype of ApoE KO was unexpectedly
abolished in DKO mice fed with WD (10). This surprising
phenotype was attributed to reduced plasma total cholesterol
(TC) and low density lipoprotein-cholesterol (LDL-C), elevated
high density lipoprotein-cholesterol (HDL-C), compensatory
increase in cholesterol catabolism via sterol 7a-hydroxylase
(Cyp7a1) and sterol 12a-hydroxylase (Cyp8b1), increased
expression of Cyp3a11 minimizing the production of toxic
bile alcohols and cholesterol, and increased cholesterol
excretion (10).
BAs are physical detergents greatly facilitating the intestinal
absorption of lipids and vitamins (11). These amphiphilic
molecules can increase cholesterol solubility to promote the
intestinal absorption of cholesterol (12). Furthermore, BAs are
the major metabolites of cholesterol excreted through the bile out
of the liver (13). They are also critical signaling molecules
mediating nutrient homeostasis and energy expenditure (14).
BAs are known to regulate their own synthesis and transport via
farnesoid X receptor (FXR) in the liver and intestine. Different
BAs have differential effects on bile acid signaling.
Chenodeoxycholic acid (CDCA) is a much more potent FXR
agonist than cholic acid (CA) (15). In studies in mice however,
CA is a more potent FXR activator then CDCA since CDCA is
rapidly converted into muricholic acids (MCAs) (16). MCAs
have different signaling and lipid solubilizing properties
compared to CDCA, they act as FXR antagonists and do not
activate G protein-coupled bile acid receptor 1 (TGR5) (17). CA
is an important mediator of the negative feedback regulation ofFrontiers in Endocrinology | www.frontiersin.org 2BAs biosynthesis in mice (18). Loss of CA from the bile acid pool
causes a decrease in the hepatic expression of a negative
regulatory factor (SHP), which in turn causes a loss of
repression of the Cyp7a1 gene and an increase in biosynthetic
output (19). In the intestine, fibroblast growth factor 15 (FGF15)
expression is induced by bile acids acting on the FXR (20). In
Cyp27a1 KO mice, CA feeding was shown to reverse the
hepatomegaly, to suppress the up-regulation of hepatic Cyp7a1
and Cyp8b1 and to restore intestinal cholesterol absorption to
normal levels after 10 days of supplementation with 0.1% CA
(21). The hepatomegaly was also almost fully reversed when
CDCA was fed (21).
We hypothesized that, like in Cyp27a1 KO mice, feeding
DKO mice with 0.1% CA or 0.1% CDCA will restore the
hepatomegaly, suppress the up-regulation of the hepatic
cytochromes and increase intestinal cholesterol absorption in
DKO mice. These metabolic changes should lead to an increase
in atherosclerosis development. To prove this, we fed DKO mice
with a WD containing either 0.1% CA (WD-CA) or 0.1% CDCA
(WD-CDCA) and studied the effect of exogenous BAs
supplementation on plasma composition, efflux cholesterol
capacity (CEC), expression of hepatic cytochromes, atherosclerotic
plaque formation and intestinal cholesterol absorption.METHODS
Chemicals
Cholic acid (CA) (C1129), chenodeoxycholic acid (CDCA)
(C9377), Oil red O (O0625), hematoxylin solution Gill no. 3
(GHS316), and eosin Y solution aqueous (HT110216) were from
Sigma-Aldrich (St Louis, MO, USA); oligonucleotides were from
Microsynth (Balgach, Switzerland); the hexanucleotide mix was
from Roche Diagnostics (Mannheim, Germany). [4-14C]
Cholesterol and [22,23-3H] b-sitosterol were obtained from
American Radiolabeled Chemical, Inc. (St Louis, MO, USA).
Animals
Animal experimentation was approved by the Ethics Committee
for Animal Experiments of the Veterinary Administration of the
Canton of Berne, Switzerland (BE64/11 and BE 48/14), and
conformed to the rules of the Swiss Federal Act on Animal
Protection. Experiments were carried out at the central animal
facility of the University of Bern.
The Bern Cyp27a1+/− mouse-breeding colony (provided by
S.K.E., University of California, San Francisco, CA, USA), was
crossed with ApoE−/− (ApoE KO) mice (Charles River
Laboratories (Sulzfeld, Germany). The resulting Cyp27a1−/−/
ApoE−/− double knock out (DKO) mouse and Cyp27a1+/+/
ApoE (ApoE KO) on C57BL/6J background were bred and
genotyped as described (22).
Mice were maintained under 12-h dark–light cycles with
unrestricted access to food and water. At the age of 5 weeks,
males (n=18) were fed a WD containing 21% fat and 0.15%
cholesterol (D-12079B; Provimi Kliba AG). A week later, animals
were divided into 3 groups and fed for 8 weeks either WD, orOctober 2020 | Volume 11 | Article 586980
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CDCA). Animals were then placed in metabolic cages for 4
days. Urine and feces were collected over 24 h for BAs
quantification on the 4th day, after 3 days of pre-adaptation.
Mice returned to their cage for 2 days and were then starved for
4 h and sacrificed by pentobarbital injection (300 mg/kg,
pentobarbital sodium, USP; Abbott Laboratories, North
Chicago, IL, USA). The animals were weighed and blood was
collected into a tube containing 20 to 50 U heparin, centrifuged
at 4°C for 15 min at 13,000 rpm and stored at −20°C until
analyzed. Organs were removed, weighed and washed with PBS.
One part was fixed in formalin at 4°C, the other frozen in liquid
nitrogen and stored at −70°C until processed. The heart and
aorta were fixed in 4% paraformaldehyde for 24 h, transferred to
PBS, and stored at 4°C until used.
A second cohort of mice was used for cholesterol absorption.
Eight weeks old mice (n = 6–7) were fed for 2 weeks with WD,
then for another 2 weeks with WD-CA or WD-CDCA. At the
end of each food regimen, cholesterol absorption was assessed by
dual isotope incorporation. Gavage was performed with 100 ml
soybean oil containing 0.1 mCi [4-14C] cholesterol and 0.2 mCi
[22,23-3H] b-sitosterol. After gavage, each mouse was
individually housed in a cage covered with Whatman paper
and had free access to food and water. Feces were collected daily
for 3 days. Samples were extracted by saponification with 5M
KOH in 50% ethanol and heated at 80°C for 1 h. Lipids were
extracted by Folch method. The extracted lipids were transferred
into scintillation vials and isotopes were counted in b-counter.
The percentage of cholesterol absorption was calculated as
follows:
14C
3H dose ratio −
14C
3H faeces ratio
14C
3H dose ratio
 100
Plasma and Tissue Biochemistry
Plasma TC, triglycerides (TG), LDL-C+VLDL-C and HDL-C
were quantified with a kit from Wako Chemicals GmbH (Neuss,
Germany), and cholesterol and cholesteryl esters (CE) with a CE
quantification kit from Calbiochem-Merck (Millipore, Zug,
Switzerland). Apolipoprotein A-1 (ApoA-1) was measured by
enzyme-linked immunosorbent assay kit from cloud-clone corp.
(Houston, TX, USA). In liver and feces homogenates, TG were
assayed using a TG quantification kit (BioVision, Mountain View,
CA, USA), and cholesterol and cholesterol esters with quantification
kit (Calbiochem-Merck Millipore, Zug, Switzerland).
BAs were quantified by gas chromatography-mass
spectrometry (GC-MS) in liver (100 mg), bile (1 µl), urine (200
µl) and feces (10–250 mg) with 400 ng 23-Nordeoxychcolic as
recovery standard, as previously done (10, 23). BAs from bile and
urine were diluted in 5 ml saline and extracted with Sep-Pack
(Waters Corp., Milford, MA, USA). Hepatic BAs were extracted
successively with 2 ml ethanol 100%, 2 ml ethanol 80%, and 2 ml
methanol at 100°C as described by Locket and Gallaher (24). The
supernatant from each extraction was collected and pooled,
evaporated, re-suspended in 5 ml water and extracted on a
Sep-Pak C18 cartridge. BAs from feces were extracted withFrontiers in Endocrinology | www.frontiersin.org 310 ml butanol/water (1:1, vol/vol) overnight and the
supernatant was collected following centrifugation for 10 min
at 3000 rpm. All the samples were submitted to subsequent
solvolysis, hydrolysis and derivatization (23).
Histology
For en face analysis, the aorta was opened longitudinally, stained
with 5% Sudan IV (Carl Roth, Karlsruhe, Germany), and pinned
onto a white Styrofoam surface for imaging.
Lesions of the aortic valve were analyzed in paraffin
embedded sections of 10 µm at 20 µm intervals for 700 µm
and stained with hematoxylin and eosin (H&E). Lesion areas
were quantified in a blinded manner by image analysis software
(ImageJ; NIH, Bethesda, MD, USA) as described (10). Sections of
paraffin embedded liver (10 µm) were stained with H&E.
Jejunums were embedded in OCT. Frozen sections of 5 mm
were air-dried, stained with Oil red O for 10 min and rinsed with
tap water for 30 min. For analyzing, 10 frames per slide were
captured on NIS-Elements F2.20 microscope (Nikon Ltd, UK) at
40× magnification. Quantification of the specific staining was
performed in a blinded manner, using the positive pixel
algorithm of ImageJ software.
RNA Extraction and Real-Time PCR in
Liver and Intestine
RNA was extracted with TRIzol Reagent (Thermo Fisher
scientific) from 100 mg liver and 0.5 cm intestine. Reverse
transcription was performed with 2 µg RNA in a reaction
containing 100 U SuperScript Reverse Transcriptase type II
(Roche, Basel, Switzerland). Real-time PCR was performed
with 100 ng cDNA/reaction. The following primers were used:
CYP 3A 1 1 (Mm00 7 3 1 5 6 7 _m1 ) , HMGR ( hm g c r )
(Mm01282499_m1), PXR (Nr1i) (Mm01344139_m1), fatty
acid synthase (Fasn) (Mm00662319_m1), SREBP2 (Srebf2)
(Mm01306292_m1), diacylglycerol acyltransferase (Dgat1)
(Mm00515643_m1) , CYP7A1 (Mm0048T4152_m1),
CYP27A1 (Mm00470430_m1), CYP8B1(Mm00501637_s1),
LXRa (Mm00443451_m1), FXR (Nr1h4) (Mm00436419_m1),
SR-B1 (Mm00450234_m1), LDLR (Mm01177349_m1), ABCA1
(Mm00442646_m1), ABCG5 (Mm00446241_m1), ABCG8
(Mm00445970_m1), SREBP-1c (Srebf-1) (Mm00550338_m1),
SHP (Nr0b2) (Mm00442278_m1), and BSEP (Abcb11)
(Mm00445168_m1), FGFR4 (Mm01341852_m1), FGF15
(Mm00433278_m1). The other primers were obtained from
Microsynth (Switzerland) and probes from Roche Diagnostics
(Germany) and are listed in Supplementary Table 1. b-Actin
(AM1720) was used as internal standard. Quantification was
performed by the relative quantification method, using DKO
mice fed with WD as calibrator.
Cholesterol Efflux
Cholesterol efflux was performed as described previously (25),
using the plasma obtained from the different groups of mice as
acceptor. Briefly, RAW264.7 cells were plated in 12-wells plates
and grown in RPMI supplemented with 100 µg/ml penicillin-
streptomycin, 1% L-glutamine and 10% fetal bovine serum (FBS)
at 5% CO2 and 100% humidity. Cells were labeled for 48 h withOctober 2020 | Volume 11 | Article 586980
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and equilibrated O/N in OptiMem. Cells were washed 2 times
and further incubated for 2 h in the presence or absence of 2%
plasma obtained from experimental animals. The medium was
collected, centrifuged for 15 min at 4°C at 2,500 rpm. Cells were
harvested, resuspended in 1 ml of distilled water and
radioactivity was counted in 100 µl aliquots. Cholesterol efflux
was calculated as percentage of labeled cholesterol released to the
medium divided by the amount of total cholesterol in the
medium and cells in each well.
Statistical Analysis
To determine statistically significant differences, t-test or one-
way ANOVA was used, followed by Tukey or Dunn’s post hoc
test for multiple comparisons. Correlations between the
parameters were tested with a Pearson’s Rank correlation tests.
The null Hypothesis was rejected if P<0.05.RESULTS
Effect of WD-CA and WD-CDCA on Body
and Organ Weights
The effect of 8 weeks’ supplementation of WDwith CA or CDCA
on organs weight on DKO mice is shown in Table 1. When
compared to WD, WD-CA had no effect on body weight (BW)
and liver weight, but slightly increased lung weight. In contrast,
WD-CDCA led to a significant reduction of liver weight, withoutFrontiers in Endocrinology | www.frontiersin.org 4affecting BW and lung weight. The weights of spleen, kidney and
brain were unaffected by exogenous BA feeding (data
not shown).
Impact of WD-CA and WD-CDCA on
Atherosclerosis Formation
Atherosclerotic plaque development was quantified in aortic
valve sections (Figures 1A, C) and en face (Figures 1B, D) in
animals fed for 8 weeks with WD, WD-CA or WD-CDCA. As
previously reported DKO mice failed to develop atherosclerosis
(10). After feeding with WD-CA, atherosclerotic plaque
increased in aortic valve sections from 0.0027 ± 0.0014 to
0.110 ± 0.028 mm2 (mean ± SEM) (P<0.001) (Figure 1C). In
en face aorta, lesions increased from 0.00 ± 0.00 to 2.16 ± 0.77
mm2 (mean ± SEM) (P<0.0001) (Figure 1D). In contrast toWD-
CA, WD-CDCA had almost no effect on atherosclerosis
development in aortic valve (Figure 1C) and en face aorta
when compared to WD (Figure 1D).
Influence of WD-CA and WD-CDCA Diets
on Lipid Composition of Plasma, Liver, and
Bile
Plasma lipoprotein profile is shown in Table 1. After WD-CA
diet, there was a ~2-fold increase of TC (P<0.01) and LDL-C
+VLDL-C (P<0.001), while HDL-C reduced almost 2-fold
(P<0.01). TG and apoA-1 levels were unchanged. WD-CDCA
had no effect on plasma lipoprotein composition when compared
to WD (Table 1). ALT and AST increased in mice fed with WD-
CA compared with WD only (P<0.001) but could not beTABLE 1 | Effect of CA and CDCA on body and organ weight, and lipid composition in plasma, liver and bile.
Parameter WD WD-CA WD-CDCA P
n=6 n= 6 n= 6
Weight
BW (g) 27.5 ± 1.2 26.9 ± 1.8 26.9 ± 1.8 NS
Liver (g) 1.8 ± 0.4 1.8 ± 0.2 1.4 ± 0.2* 0.009
Liver/BW 6.5 ± 1.5 6.7 ± 1 5.4 ± 0.7 0.0334
Lung (g) 0.16 ± 0.02 0.18 ± 0.02* 0.16 ± 0.01 0.0112
Lung/BW 5.6 ± 0.5 6.8 ± 1* 5.7 ± 0.4 0.0269
Plasma
TC (mmol/l) 8.8 ± 1.3 21.8 ± 4.4** 9.4 ± 1.9 0.0004
HDL-C (mmol/l) 0.81 ± 0.07 0.45 ± 0.04** 0.65 ± 0.15 0.0006
LDL+VLDL-C (mmol/l) 7.8 ± 1.9 15.2 ± 4.0*** 8.5 ± 1.9 0.0005
TG (mmol/l) 1.9 ± 0.7 2.1 ± 0.9 1.3 ± 0.8 NS
ApoA-I (mg/dl) 93.4 ± 40.8 131.7 ± 39.2 113.9 ± 50 NS
AST (IU/l) 18 ± 6 32 ± 8** n.m. 0.0049
ALT (IU/l) 227 ± 44 418 ± 79** n.m. 0.0049
Cholesterol efflux (%) 3.1 ± 0.3 2.4 ± 0.5* 3.1 ± 0.7 0.0458
Liver
TC (mg/mg) 6.7 ± 1.3 16.2 ± 3.6*** 7.4 ± 2.7 0.0001
CE (mg/mg) 1.3 ± 0.8 2.9 ± 0.8** 1.5 ± 0.5 0.0011
TG (nmol/mg) 61.6 ± 13.8 28.2 ± 9.9*** 37.2 ± 10.8** 0.0005
Bile
TC (mmol/10ml) 1.6 ± 0.7 11.1 ± 3.1*** 3.9 ± 1.1 0.0001October 2020 | Volume 11 | Article 58698Results are presented as means ± SEM.
For statistical significance, *P < 0.05, **P < 0.01, ***P < 0.001 vs. WD.
NS, not significant.
n.a., not applicable.0
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CA and CDCA feeding also modified hepatic lipids
composition. TC and CE content doubled after WD-CA
feeding (P<0.0001 and P<0.01) but remained constant with
WD-CDCA feeding when compared to WD alone (Table 1).
Both WD-CA and WD-CDCA feedings reduced liver TG
content by about 50% (P<0.01 and P<0.001) (Table 1). In the
bile, the amount of TC increased 7 fold when mice were fed with
WD-CA and 2.5 fold in mice fed with WD-CDCA (P<0.001)
(Table 1).
Effect of WD-CA and WD-CDCA Diets on
Plasma Efflux Capacity
To test the effect of BAs on HDL functionality, cholesterol efflux
was performed in RAW 264.7 cells, using plasma obtained from
experimental mice. Cholesterol efflux was reduced when
macrophages were incubated with plasma from mice fed with
WD-CA (P<0.05) (Table 1). Cholesterol efflux correlated with
plasma HDL-C (R2 = 0.373, r=0.611, P<0.001).
Contribution of WD-CA and WD-CDCA
Feeding to Changes in BAs Amount
and Composition
Similar amounts of CA and CDCA were ingested, as calculated
from food intake when mice were in metabolic cages (Table 2).
BA content was measured in liver, bile, feces and urine
(Table 2). Mice fed with WD-CA had markedly elevated BAs
in liver (P<0.01) whereas those fed with WD-CDCA hadFrontiers in Endocrinology | www.frontiersin.org 5increased total BAs in liver (P<0.05), bile (P<0.05) and feces
(P<0.01) when compared to those fed with WD alone. The
amount of total BAs did not change in urine with both diets
(Table 2).
The analysis of bile acid composition revealed in animals fed
with WD-CA a 32-fold increase of CA in the liver (P<0.05) and
4-fold increase in feces (p<0.01), representing 0.76 ± 0.23% and
1.69 ± 0.36% respectively of the ingested CA (Table 2). Content
of the secondary BA, deoxycholic acid (DCA) metabolized from
CA, also increased 10-fold in the liver (P<0.01) and feces
(P<0.001), contributing 1to the excretion of 0.05 ± 0.01% and
1.50 ± 0.16% respectively of the ingested CA. The content of LCA
markedly decreased in feces but represented only 0.005 ± 0.002%
of the ingested CA (P<0.01) (Table 2). No significant changes
were observed in urine in which BAs excretion was 50 fold lower
when compared to feces P<0.0001).
In mice fed with WD-CDCA, CDCA content increased more
than 20 fold in liver and feces (P<0.05 and P<0.001) and 2.5 fold
in the bile (P<0.05), but urinary excretion remained constant
(Table 2). The increase in total BA content in the liver was not
only due to the accumulation of CDCA, but also to the presence
of a-muricholic acid (aMCA), b-muricholic (bMCA), w-
muricholic (wMCA), and UDCA, representing 0.07 ± 0.03%,
0.10 ± 0.02%, 0.11 ± 0.01%, 0.04 ± 0.01% and 0.12 ± 0.04% of the
ingested CDCA (Table 2). In the liver, aMCA increased more 30
fold (P<0.001), bMCA and wMCA increased 4 fold (P<0.001 and
P<0.01) and combined the 3 MCAs constituted more than half of
the BAs pool. The same tendency was seen in bile. The most
pronounced changes in BA composition was observed in feces
where more than 90% of BAs consisted of MCAs, whereas inA B
DC
FIGURE 1 | Effect of WD, WD-CA, and WD-CDCA on the development of atherosclerosis in DKO mice. Mice were fed for two months with the appropriate diet and
atherosclerosis was quantified in aortic valve sections and en face. (A) Representative photomicrographs of aortic valve in paraffin-embedded sections stained with H&E.
Scale bars 200 µm. (B) Representative en face Sudan IV staining of aorta. Scale bars 1 mm. (C) Quantification of atherosclerotic lesions in aortic valve [mm2].
(D) Quantification of atherosclerotic lesions in en face aorta [mm2]. Arrows indicate atherosclerotic plaques. Data are means ± SEM. For statistical significance, **P < 0.01.October 2020 | Volume 11 | Article 586980
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excretion. Ursodeocycholic acid (UDCA) and hyodeoxycholic
acid (HDCA) content were also significantly increased (P<0.01
and P < 0.001), but they represented a smaller proportion of BA
(Table 2). In total, 28.02 ± 3.18% of the ingested CDCA was
excreted (as CDCA but also as UDCA, LCA, HDCA and MCAs)
in feces. The only change in urinary BA composition was a slight
decreased (P<0.05) in LCA.Frontiers in Endocrinology | www.frontiersin.org 6Effect of WD-CA and WD-CDCA Diets on
Liver Histology
Histology analyses of the liver revealed that all mice fed withWD
suffered from macrovesicular steatosis. The condition was
slightly more severe in animals fed with WD-CA (Figure 2A).
There was some microvesicular steatosis specific for mice fed
with WD and WD-CA but not WD-CDCA. Ballooning
degeneration of hepatocytes was observed in mice fed WDTABLE 2 | Quantification of BA intake and BA composition in liver, bile juice, faeces and urine.
BA WD WD-CA WD-CDCA One way Anova
n= 6 n= 6 n= 6 P
Food CA none 9.38 ± 2.19 none n.a.
[mmol/24h] CDCA none none 10.64 ± 1.5 n.a.
Liver
[nmol/g] BAs total 7.45 ± 1.26 91.95 ± 25.89** 48.9 ± 8.90* 0.0002
CA 2.26 ± 0.55 71.17 ± 22.44* 1.15 ± 0.26 0.0001
CDCA 0.27 ± 0.03 0.18 ± 0.01 7.92 ± 2.70* 0.0001
aMCA 0.37 ± 0.04 0.48 ± 0.03 10.74 ± 2.13** 0.0001
bMCA 2.60 ± 0.74 1.50 ± 0.41 11.61 ± 1.40*** 0.0001
wMCA 0.80 ± 0.07 0.72 ± 0.12 3.77 ± 0.69 0.0003
UDCA 0.42 ± 0.06 0.08 ± 0.04 12.63 ± 3.78** 0.0041
DCA 0.57 ± 0.08 4.97 ± 0.98** 0.72 ± 0.05 0.0002
LCA ND ND ND ND
HDCA 0.20 ± 0.02 0.17 ± 0.05 0.35 ± 0.07 NS
Bile juice
[pmol/ml] Bas total 81.30 ± 4.05 172.00 ± 46.23 176.50 ± 9.61* 0.029
CA 10.73 ± 2.14 90.68 ± 35.43 14.81 ± 0.84 NS
CDCA 8.39 ± 0.31 7.67 ± 0.12 21.26 ± 4.472* 0.0138
aMCA 7.73 ± 0.20 22.98 ± 10.03 28.57 ± 1.64 NS
bMCA 10.53 ± 0.47 9.64 ± 0.52 50.18 ± 4.80*** 0.0001
wMCA 13.42 ± 2.17 10.44 ± 0.79 20.48 ± 2.57 0.0221
UDCA 9.46 ± 0.19 8.36 ± 0.14 18.13 ± 1.91 0.0001
DCA 7.14 ± 0.17 7.57 ± 0.35 6.68 ± 0.12 NS
LCA 8.50 ± 0.18 7.44 ± 0.13 7.81 ± 0.15 NS
HDCA 8.38 ± 0.16 7.27 ± 0.14 8.57 ± 0.20 NS
Feces
[nmol/24h] Bas total 253.0 ± 18.7 357 ± 49 3044 ± 269.3** 0.0001
CA 40.1 ± 5.3 158.9 ± 34.2** 59.9 ± 9.4 0.0008
CDCA 3.2 ± 0.3 0.4 ± 0.1 68.6 ± 12.8*** 0.0001
aMCA 10.1 ± 2.0 1.7 ± 0.3 532.1 ± 101.6*** 0.0001
bMCA 17.8 ± 5.0 8.6 ± 2.5 785.2 ± 96.8* 0.0001
wMCA 122.2 ± 14.5 40.2 ± 8.2 1520.0 ± 196.2*** 0.0001
UDCA 4.5 ± 0.7 2.9 ± 0.4 58.2 ± 8.0** 0.0009
DCA 14.3 ± 1.7 140.8 ± 15.7*** 23.0 ± 2.1 0.0001
LCA 22.7 ± 6.0 0.4 ± 0.1** 10.2 ± 2.9 0.0037
HDCA 18.2 ± 2.3 2.7 ± 0.3 86.3 ± 13.5*** 0.0001
Urine
[nmol/24h] Bas total 3.22 ± 0.83 6.21 ± 2.32 9.90 ± 4.36 NS
CA 1.41 ± 0.58 6.80 ± 3.74 0.12 ± 0.07 NS
CDCA 0.03 ± 0.01 ND 0.23 ± 0.13 NS
aMCA 0.02 ± 0.01 0.01 ± 0.01 0.27 ± 0.20 NS
bMCA 0.07 ± 0.03 0.02 ± 0.01 0.34 ± 0.20 NS
wMCA 0.97 ± 0.36 0.69 ± 0.19 4.32 ± 2.77 NS
UDCA 0.06 ± 0.02 0.05 ± 0.01 1.43 ± 0.84 NS
DCA 0.08 ± 0.04 0.05 ± 0.02 0.01 ± 0.00 NS
LCA 0.09 ± 0.02 0.10 ± 0.03 0.02 ± 0.01* 0.0089
HDCA 0.15 ± 0.04 0.03 ± 0.02 0.07 ± 0.03 NSOctober 2020 | Volume 11Results are presented as means ± SEM.
For statistical significance, *P < 0.05, **P < 0.01, ***P < 0.001 vs. WD.
NS not significant.
n.a. not applicable.
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present (Figure 2A).
Impact of WD-CA and WD-CDCA Diets on
Expression of Liver Genes Involved in
Lipid Metabolism and Inflammation
Gene expression results are summarized in Table 3. First, we
assessed the effect of CA and CDCA on the expression of genes
involved in cholesterol metabolism. The mRNA for Cyp7a1 and
Cyp3a11, two genes involved in BAs metabolism and
detoxification, decreased 3-fold (P<0.01) and 2-fold (P<0.001)
respectively with both diets. Expression of Cyp8b1, a key
determinant of CA production, decreased more than 10-fold in
mice fed with WD-CA (P<0.001) and did not change
significantly in those fed with WD-CDCA. The expression of
genes involved in cholesterol homeostasis, HMGCR (Hmgcr),
sterol regulatory element-binding protein 2 (Srebf2) and low
density lipoprotein receptor (Ldlr) significantly decreased in
animals fed with WD-CA (P< 0.01, P<0.001 and P<0.05). The
effect was specific for CA except for Srebf2 expression of which
was also reduced by WD-CDCA (P<0.01) (Table 3).
Among BAs transporters investigated, expression of Slc51b,
the gene for organic solute transporter b (OSTb), increased more
than 5-fold with WD-CA (P<0.01), whereas expression of
Slc10a1, the gene for sodium/bile acid cotransporter (NTCP),
increased specifically with CD-CDCA (P<0.05). The expression
of Slco1a1 (gene for organic-anion-transporter protein
[OATP1]), Gpbar1 (gene for G protein-coupled bile acid
receptor 1 [TGR5]) and Abcb11 (gene for the bile salt export
pump [BSEP]) remained unchanged (Table 3). The reasons forFrontiers in Endocrinology | www.frontiersin.org 7an inconsistency in the effects of BAs on the expression of OSTb
and Abcb11 when both genes are activated by FXR are not clear,
but are likely attributed to Cyp27a1 deficiency.
For genes involved in cholesterol transport, we observed a 3-
fold increase in Abcg1 expression (P<0.001), a more than 2-fold
increase in expression of Abcg8 (P<0.001) and Abcg5 (P<0.05),
and a slight increase in expression of Abca1 (P<0.001) in WD-
CA fed animals (Table 3). The expression of Nr1h3 (gene for
Liver X receptor [LXR]) and Cav-1 (gene for caveolin-1) were
reduced (P<0.01), and the expression of Scarb1 (SR-B1)
remained unchanged. Similar, but less pronounced effects on
the exception of Nr1h3 were observed with WD-CDCA
(Table 3).
WD-CA and WD-CDCA diets did not change the expression
levels of the nuclear receptors Nrli2 (gene for PXR) and Nrlh4
(gene for FXR) but increased expression of Nr0b2 (gene for small
heterodimer protein [SHP]) (P<0.01). WD-CA diet enhanced
expression of Vdr (P<0.01) and decreased expression of Ffg4
(P<0.05) (Table 3).
Among genes involved in fatty acid and triglycerides synthesis
(Table 3), expression of the transcription factor peroxisome
proliferator activated receptor gamma (Pparg) and fatty acid
synthase (Fas) decreased 3- to 4-fold (P<0.01 and P<0.001), and
expression of diglyceride acyltransferase (Dgat-1) decreased
slightly (P<0.01) in mice fed with WD-CA but not with WD-
CDCA. In contrast, the expression of Srebf1, the gene for SREBP-
1c, increased in mice fed WD-CDCA (P<0.001).
Changes in expression of markers of inflammation were
scarce (Table 3). Expression of tumor necrosis factor a (Tnfa)
increased more than 2-fold with WD-CA diet (P<0.01) but notA
B
FIGURE 2 | Effect of WD, WD-CA, and WD-CDCA on liver and jejunum. (A) Representative photomicrographs of H&E staining of liver (A) and Oil red O staining of
jejunum (B) sections of DKO mice fed for 2 months with WD, WD-CA or WD-CDCA. Scale bars 20 µm for liver, 50 µm for ileum. In liver, thick arrows indicate
ballooning degeneration of hepatocytes, and thin arrows designate cleared hepatocytes.October 2020 | Volume 11 | Article 586980
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remained unchanged.
Effect of WD-CA and WD-CDCA Diets on
Cholesterol Absorption and Gene
Expression in the Intestine
The effect of exogenous CA and CDCA diets on cholesterol
absorption was measured using the dual isotope incorporation
method (Figure 3A). Cholesterol absorption increased more
than 5-fold in mice fed WD-CA and 3-fold in mice fed WD-
CDCA (P<0.0001). In mice fed with WD-CA, the more than 4-
fold reduced daily fecal total cholesterol fecal output (P<0.0001)
is due to an increased in cholesterol absorption (P<0.0001)
(Figure 3B). WD-CA diet also reduced TG elimination with
feces by a 2-fold (P<0.05), whereas fecal levels of CE and BAs
remained unchanged (Figure 3B). In contrast, in mice fed with
WD-CDCA, BAs excretion was more than 10-fold higher
compared to mice fed with WD (Figure 3B).
Cholesterol esters and TG accumulation were assessed in
enterocytes by Oil red O staining in the ileum (Figure 2B). The
intensity of the staining was reduced by 50% with CA and
increased by 33% with CDCA (P<0.0001) (Figure 3C).
The analysis of gene expression in the intestine is reported in
Table 4. Interestingly, in the ileum, the genes involved in
cholesterol homeostasis were similarly downregulated in miceFrontiers in Endocrinology | www.frontiersin.org 8fed with WD-CA and WD-CDCA, except for Cyp3a11 which
was markedly suppressed only with WD-CDCA. The most
dramatic increase was for the molecular targets of Fxr, fibroblast
growth factor (Fgf15) and SHP. Fgf15 expression increased 500-
fold (P<0.0001) and expression of Nr0b2 (SHP) increased 1000-
fold (P<0.001) (Table 4) in mice fed with WD-CA. WD-CDCA
diet also increased the expression of these two genes, but to a lesser
extent. Slc51a (OSTa) expression was upregulated (P<0.01), but
only in mice fed WD-CA and the same tendency was observed for
Slc51b (OSTb). Expression of all the genes involved in cholesterol
efflux, Abca1, Abcg1, Abcg5, Abcg8, and Scarb1 were increased in
mice fed with WD-CA, with the biggest increase in Abca1
expression (P<0.01). This was not observed for animals fed with
WD-CDCA, as the only change observed when compared to WD
was the reduction of expression of Abcg1 (P<0.001).
Finally, we analyzed gene expression of the intestinal
cholesterol transporter, the transmembrane protein Niemann-
Pick C1-Like 1 protein (NPC1L1) in the jejunum. InWD-CA fed
mice, there was a significant decrease in mRNA expression when
compared to animals fed with WD or WD-CDCA (P<0.05).
Effect of WD-CA and WD-CDCA Diets on
ApoE KO Mice
To investigate the effect of WD-CA and WD-CDCA in mice with
normal Cyp27a1 expression, atherosclerotic lesions were quantifiedTABLE 3 | Effect of CA and CDCA on expression of genes involved in lipid metabolism and inflammation in the liver.
Role Gene WD WD-CA WD-CDCA One way Anova
n=6 n=6 n= 6 P
Cholesterol homeostasis Cyp7a1 1.04 ± 0.32 0.37 ± 0.18** 0.38 ± 0.28** 0.0006
Cyp3a11 1.01 ± 0.19 0.48 ± 0.17*** 0.48 ± 0.12*** 0.0001
Cyp8b1 1.01 ± 0.17 0.08 ± 0.04*** 0.65 ± 0.18 0.0008
Hmgcr 1.06 ± 0.40 0.13 ± 0.06** 0.62 ± 0.36 0.0051
Srebf2 (SREBP2) 1.01 ± 0.16 0.27 ± 0.04*** 0.68 ± 0.19** 0.0001
Ldlr 1.07 ± 0.39 0.38 ± 0.10* 0.94 ± 0.25 0.0153
BAs signaling Slco1a1 (OATP1) 1.01 ± 0.15 0.91 ± 0.34 1.19 ± 0.29 NS
Slc10a1 (NTCP) 1.10 ± 0.52 0.44 ± 0.25 2.07 ± 0.71* 0.0003
Slc51b (OSTb) 1.09 ± 0.50 6.46 ± 2.61** 1.26 ± 0.69* 0.0047
Abcb11 (BSEP) 1.01 ± 0.12 0.85 ± 0.19 1.11 ± 0.21 NS
Fgf4 1.00 ± 0.12 0.79 ± 0.13* 0.96 ± 1.14 0.0287
Cholesterol transport Abca1 1.02 ± 0.20 1.50 ± 0.21*** 1.43 ± 0.10** 0.0005
Nr1h3 (LXRa) 1.01 ± 0.13 0.73 ± 0.15** 0.93 ± 0.08 0.0034
Abcg1 1.02 ± 0.23 3.06 ± 0.41*** 1.52 ± 0.22* 0.0001
Abcg5 1.03 ± 0.24 2.27 ± 0.71* 1.50 ± 0.19* 0.013
Abcg8 1.03 ± 0.29 2.37 ± 0.66*** 1.75 ± 0.40* 0.0007
Scarb1 (SR-B1) 1.02 ± 0.22 1.20 ± 0.22 1.09 ± 0.21 NS
Cav-1 1.01 ± 0.15 0.50 ± 0.31** 0.58 ± 0.21* 0.0034
Nuclear receptors Nr1i2 (PXR) 1.01 ± 0.19 0.80 ± 0.26 1.09 ± 0.17 NS
Nr1h4 (FXR) 1.06 ± 0.35 0.79 ± 0.27 1.39 ± 0.31 0.0146
Nr0b2 (SHP) 1.31 ± 1.29 3.68 ± 1.07** 2.97 ± 0.89* 0.0059
Vdr 1.09 ± 0.45 5.70 ± 3.06** 1.44 ± 0.50 0.0008
Rxra 1.02 ± 0.22 0.77 ± 0.23 1.19 ± 0.27 0.0302
Fatty acids and TG biosynthesis Pparg 1.04 ± 0.32 0.31 ± 0.06** 0.88 ± 0.17 0.0024
Fasn 1.02 ± 0.24 0.25 ± 0.08*** 0.88 ± 0.36 0.0085
Dgat1 1.01 ± 0.14 0.67 ± 0.15** 1.03 ± 0.12 0.0005
Srebf1 (SREBP-1c) 1.05 ± 0.35 1.54 ± 0.57 2.33 ± 0.39*** 0.0007
Inflammation Tnfa 1.06 ± 0.38 2.34 ± 0.80** 0.94 ± 0.34 0.0008
Il6 1.13 ± 0.60 0.53 ± 0.30 0.73 ± 0.36 NSOctober 2020 | Volume 11Results are presented as means ± SD.
For statistical significance, *P < 0.05, **P < 0.01, ***P < 0.001 vs. WD.
NS not significant.| Article 586980
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DKOmice, WD-CA was pro-atherogenic leading to a 75% increase
in atherosclerotic lesions (P<0.05), whereas WD-CDCA had no
effect on the size of the atherosclerotic lesions (Figure 4A). This
phenotype could be explained by a 25% increase in cholesterol
absorption specific for WD-CA (P<0.001) (Figure 4B) and a
different plasma lipid composition (Figure 4C), mainly because
LDL-C increased by a factor 2 (P<0.01) (Figure 4C). Notably,
cholesterol absorption in ApoE KO mice fed WD alone was almost
5-fold higher than in DKO mice (compare Figs. 4B and 3A). WD-
CA had no significant effect on hepatic Cyp7a1, Cyp3a11, and
Cyp27a1 mRNA levels (Figure 4D). Nevertheless, when compared
to DKO mice fed with WD-CA and WD-CDCA, the expression of
Cyp3a11 in the liver was still lower in ApoE KO (Figure 4D). This
was not the case for Cyp7a1 (Figure 4D).DISCUSSION
In our previous study, Cyp27a1 deficient mice on ApoE−/−
background, (DKO mice), fed with WD developed 10-fold less
atherosclerosis than their ApoE KO littermates (9). Increased
cholesterol metabolism via over-expression of hepatic Cyp7a1
and Cyp3a11 gene expression and reduced cholesterol
absorption were proposed as atheroprotective mechanisms.
Since feeding Cyp27a1 KO mice with CA or CDCA reversed
the metabolic features of Cyp27a1 deficient mice (14), we applied
a similar treatment to DKO mice fed with WD and re-assessed
their phenotype.
The key findings of our study are summarized in Figure 5.
Like in Cyp27a1 KO mice, CA and CDCA down regulated
expression of hepatic Cyp7a1 and Cyp3a11 to the same extend.Frontiers in Endocrinology | www.frontiersin.org 9However, treatment with exogenous BAs differently modified
gene expression in the liver and intestine, plasma lipids
composition and cholesterol absorption. This lead to a
different hepatic and atherosclerotic phenotype in Cyp27a1
deficient mice on ApoE background fed with WD.
WD-CA fed DKO mice had increased atherosclerotic plaque
formation, a finding attributed predominantly to the elevated
plasma TC and LDL-C (Table 1) combined with increase of
intestinal cholesterol absorption and decreased fecal output of
cholesterol. The increase in plasma lipids is likely explained by
the reduced hepatic expression of Srebf2 and Ldlr (Table 3),
leading to a decreased LDL uptake by the liver. The measurement
of in vivo cholesterol absorption and fecal output (Figures 3A,
C) confirmed an increased cholesterol absorption and reduced
fecal output, two elements likely accounting for the pro-
atherogenic plasma lipoprotein composition and the
atherosclerotic plaque formation. However, we observed
increased expression of Abcg5/g8 and reduced expression of
Npc1l1 in the intestine, a phenotype usually associated with
reduced cholesterol absorption (19). This is counterintuitive,
but may point to a compensatory response to the changes
caused by a different mechanism. Changes in ABCG5/G8
expression were shown to have little impact on plasma
cholesterol level (19). Moreover, fecal excretion might have
been underestimated, as we did not measure coprostanol and
coprostanone. The hepatotoxic effect of CA feeding could also
contribute to the diminished hepatic uptake of cholesterol and
the development of atherosclerosis. Finally, WD-CA affected the
entero-hepatic circulation by increasing massively the expression
of Ffg15 in the intestine.
In contrast to DKO mice fed with WD-CA, DKO mice fed
WD-CDCA did not develop atherosclerotic lesions, a phenotypeA B
C
FIGURE 3 | Effect of WD, WD-CA, and WD-CDCA on cholesterol elimination. (A) Cholesterol absorption, measured via dual isotope incorporation method.
(B) Quantification of neutral lipid in ileum in arbitrary units [a.u.]. (C) Fecal lipid content expressed as daily excretion of TC, cholesterol ester (CE), TG and BAs.
Results are presented as mean ± SD, n=6. For statistical difference, *P<0.05, **P<0.01,***P<0.001, ****P<0.0001.October 2020 | Volume 11 | Article 586980
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Role Gene WD WD-CA WD-CDCA One way Anova
n=6 n=6 n= 6 P
Cholesterol homeostasis Cyp3a11 1.08 ± 0.46 1.00 ± 0.70 0.34 ± 0.15* 0.0091
Hmgcr 1.01 ± 0.14 0.63 ± 0.07*** 0.79 ± 0.14* 0.0003
Srebf2 (SREBP2) 1.01 ± 0.15 0.97 ± 0.19 0.82 ± 0.06 NS
Ldlr 1.03 ± 0.29 0.74 ± 0.14* 0.67 ± 0.13* 0.0158
BAs signaling Slc51a (OSTa) 1.01 ± 0.13 2.47 ± 0.71** 1.36 ± 0.52 0.0019
Slc51b (OSTb) 1.09 ± 0.55 1.70 ± 0.47 1.19 ± 0.31 NS
Slc10a2 (ASBT) 1.01 ± 0.13 0.78 ± 0.19 0.90 ± 0.23 NS
Gpbar1 (TGR5) 1.07 ± 0.51 1.83 ± 0.45 1.12 ± 0.46 NS
Fgf15 1.14 ± 0.57 487 ± 184*** 63.9 ± 30.2 0.0001
Cholesterol transport Abca1 1.05 ± 0.37 5.18 ± 1.2** 1.16 ± 0.28 0.0018
Nr1h3 (LXRa) 1.03 ± 0.17 1.35 ± 0.34 1.17 ± 0.27 NS
Abcg1 1.06 ± 0.45 3.50 ± 0.83*** 0.58 ± 0.18** 0.0001
Abcg5 1.01 ± 0.19 2.51 ± 0.67*** 1.50 ± 0.19 0.0001
Abcg8 1.02 ± 0.23 3.10 ± 0.65*** 1.52 ± 0.29 0.0001
Scarb1 (SR-B1) 0.89 ± 0.11 1.74 ± 0.39*** 0.64 ± 0.26 0.0001
Cav-1 0.84 ± 0.09 1.66 ± 0.62 0.69 ± 0.39 0.019
Npc1l1 1.02 ± 0.13 0.54 ± 0.05* 1.05 ± 0.07 0.0014
Nuclear receptors Nr1i2 (PXR) 1.00 ± 0.11 1.75 ± 0.10** 1.29 ± 0.16** 0.0001
Nr1h4 (FXR) 1.02 ± 0.19 1.25 ± 0.20*** 1.05 ± 0.33 NS
Nr0b2 (SHP) 1.08 ± 0.54 1098 ± 589*** 11.7 ± 4.6 0.0001
Vdr 1.00 ± 0.11 1.44 ± 0.21** 1.02 ± 0.20 0.003
Rxra 1.00 ± 0.09 1.41 ± 0.20** 0.99 ± 0.13 0.0007Frontiers in Endocrinology | www.frontiersin.org 10 October 2020 | Volume 11 | Article 586Results are presented as means ± SD.
For statistical significance, *P < 0.05, **P < 0.01, ***P < 0.001 vs. WD.
NS not significant.A
B D
C
FIGURE 4 | Effect of WD, WD-CA, and WD-CDCA on cardiovascular and metabolic changes in ApoE KO mice. Atherosclerotic lesions were quantified in aortic
valve sections (A). Cholesterol absorption was measured with dual isotope incorporation (B). Plasma lipid composition (C) was measured by chemoluminescence.
Cyp3a11, Cyp7a1 and Cyp27a1 mRNA levels were measured in liver (D). Results are presented as means± SD. For statistical difference ***P < 0.001, **P < 0.01,
and *P < 0.05; &&&P < 0.001 when compared to DKO mice with the same food regimen.980
Zurkinden et al. Atherosclerosis in Cyp27a1/ApoE DKO micelikely attributed to low plasma TC an LDL-C (Table 1) combined
with decreased intestinal cholesterol absorption and increased
BAs excretion (mainly aMCA, bMCA and wMCA) into feces
(Table 2). The more hydrophilic composition of bile acid pool as
a consequence of accumulation of muricholic acids is highly
likely responsible for the lesser induction of cholesterol
absorption by WD-CDCA than with WD-CA. With normal
levels of hepatic LdlrmRNA (Table 3), cholesterol uptake by the
liver was not enhanced. Intestinal cholesterol absorption was also
preserved, since expression of both Abca1 and Abcg5/g8 were not
up-regulated (Table 4).
The difference in atherosclerotic plaque formation between
the two groups of DKO mice could partly be explained by a
decrease in reverse cholesterol transport (RCT). In the present
study, we analyzed two steps of RCT, first step, the transport of
cholesterol to an acceptor in plasma, cholesterol efflux, and the
last step, elimination of cholesterol via BAs. DKO mice plasma’s
acceptor capacity from mice fed with WD-CA was reduced when
compared to WD or WD-CDCA, and the efflux correlated to
HDL-C. BAs excretion in feces was 10-fold higher with WD-
CDCA feeding than with WD-CA feeding. Thus, reduced RCT
upon feeding WD-CA may also contribute the formation of
atherosclerotic lesions in DKO mice.
The difference in cholesterol absorption between the WD-CA
and WD-CDCA fed mice could also be due to the different
critical micelle concentration (CMC) of these two BAs. This
important physico-chemical parameter reflects the propensity toFrontiers in Endocrinology | www.frontiersin.org 11form miscellar aggregates and to facilitate the transport of
liposoluble molecules, such as cholesterol; it is a relevant
parameter for evaluation of the biological activity of a BA.
With a low CMC, CA is much more efficient than CDCA in
facilitating the absorption of dietary cholesterol from WD
(26, 27).
FXR is known to play a key role in the regulation of bile acid
synthesis and homeostasis. Whereas CA and CDCA are known
FXR agonists, MCAs are FXR antagonists (11). Previously, Qi
et al. (20) suggested that reducing 12a-hydroxylated BAs and
increasing intestinal Tauro-b-MCA, an antagonist of FXR, may
reduce high fat diet-induced increase of phospholipids,
sphingomyelins and ceramides and ameliorate diabetes and
obesity. In this study, we found a very pronounced increase of
all 3 MCAs, aMCA, bMCA and wMCA in feces of mice fedWD-
CDCA, pointing indirectly to the importance of these BAs in the
prevention of atherosclerosis, whereas in WD-CA fed mice, they
remained unchanged.
Interestingly, our treatment did not reverse the hepatomegaly
as described by Repa et al. for Cyp27a1 deficient mice (14),
despite the fact that similar doses of CA and CDCA were used.
Our DKO mice fed with WD suffered from hepatomegaly with
macrovesicular steatosis, and the latter was more severe in WD-
CA fed mice. The increase in total cholesterol and cholesteryl
ester in the liver (Table 1) confirmed this histological
observation. In contrast, both liver and the liver/body weight
ratio were decreased in DKO mice fed with WD-CDCAFIGURE 5 | Possible atherosclerotic mechanisms. Hepatic CYP7A1 and CYP3A11 were downregulated to the same level with both diets but only WD-CA was
atherogenic. (A) In WD-CA fed mice, atherosclerosis was mainly driven by high circulating TC concentrations, low HDL-C and high LDL-C, and reduced cholesterol
output in feces. The increased plasma LDL-C was attributed to the reduced LDLR leading to a diminished LDL-C uptake by the liver, driven by a decreased
SREPB2. In the intestine, WD-CA promoted the release of FGF15 as well as increased expression of ABCA1, ABCG5, ABCG8, and SR-B1. (B) WD-CDCA fed mice
failed to develop atherosclerosis, because of low plasma cholesterol, high HDL-C and low LDL-C, the tremendous increase of BAs excretion in feces. In the intestine,
WD-CDCA also strongly down regulated CYP3A11, whereas FGF-15 was slightly increased and ABCA1 and ABCG5/G8 were unchanged.October 2020 | Volume 11 | Article 586980
Zurkinden et al. Atherosclerosis in Cyp27a1/ApoE DKO mice(Table 1). The difference between Repa’s study and ours can be
explained by i) the different background, specifically, ApoE
deficiency, ii) the high fat and high cholesterol content of the
WD and iii) the duration of BAs treatment.
Like in DKOmice, WD-CA was pro-atherogenic in ApoE KO
mice with normal Cyp27a1 expression, mostly because of
increased plasma LDL-C and cholesterol absorption.
Interestingly, the amount of atherosclerotic plaque in the aortic
valve was of the same magnitude in ApoE KO and DKOmice fed
with WD-CA: they had similar levels of plasma TC, cholesterol
absorption and Cyp7a1 hepatic mRNA. DKOmice fed withWD-
CA however had still lower LDL-C and increased hepatic
Cyp3a11 mRNA expression when compared to their ApoE KO
littermates. This indicates that Cyp3a11 is still a major key player
of the athero-protective mechanism in DKO mice fed with WD-
CA. In ApoE KO mice fed with WD-CDCA, the amount of
atherosclerotic plaque was higher than in DKOmice fed with the
same food regimen. This is best explained by the pro-atherogenic
lipid profile (higher TC, lower HDL-C and higher LDL-C) and
the increased cholesterol absorption in ApoE KO mice.
Humans with a loss of function mutation in the CYP27A1
gene suffer from Cerebrotendinous xanthomatosis (CTX). This
autosomal recessive disease is characterized by an accumulation
of cholesterol, cholestanol and bile alcohols in peripheral tissues,
despite normal and slightly decreased circulating total
cholesterol and LDL-C concentrations, indicating a defect in
RCT. Interestingly, some but not all develop a severe
atherosclerosis (21-24). The usual treatment which consists of
CDCA 2–3 × 250 mg daily, has no toxic effect on the liver. The
variation of development of atherosclerosis in CTX patients
could eventually be explained by the relative expression of
CYP3A11 and CYP7A1, but it remains to be proven.
One limitation of the study is that we could not measure bile
alcohols, cholestetanol and oxysterols in plasma because of the
limitation of size sample. A second limitation is that we based
our conclusions on assessment of mRNA levels alone.
Posttranscriptional events that may be relevant for the
biological actions have not been considered here.
In conclusion, experimental treatment of CYP27A1 deficiency
with two different BAs had very different metabolic consequences
and cardiovascular outcomes, demonstrating that current view ofFrontiers in Endocrinology | www.frontiersin.org 12how BA infusion works is simplistic. A better understanding of
exact mechanisms of how BAs regulate lipid metabolism and if
BAs have a direct effect on gene expression in macrophages is
essential for development of future therapies involving BAs.DATA AVAILABILITY STATEMENT
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